Ironwood Pharmaceuticals to acquire Swiss biotech company VectivBio

Ironwood Pharmaceuticals to acquire Swiss biotech company VectivBio

Ironwood Pharmaceuticals, a gastrointestinal (GI)-focused healthcare company, has agreed to acquire VectivBio Holding AG, a Switzerland-based biotech company, listed on the Nasdaq, for around $1 billion, including the latter’s debt. Shareholders of VectivBio will be paid $17 per share in cash. VectivBio is a clinical-stage biopharmaceutical company headquartered in Basel, specializing in the development of […]

French biotech company Amolyt Pharma Series C round fetches $138m

French biotech company Amolyt Pharma Series C round fetches $138m

Amolyt Pharma, a France-based clinical-stage biotechnology company, has secured €130 million (around $138 million) from a Series C equity financing round led by Sofinnova Partners and co-led by Intermediate Capital Group (ICG). The French biotech company anticipates using the funding to advance its pipeline of therapeutics for rare endocrine and related disorders, including AZP-3601 and […]

Chinese biopharma company Akeso raises $150m for antibody drug discovery

Chinese biopharma company Akeso raises $150m for antibody drug discovery

Akeso, a Chinese biopharma company engaged in antibody drug discovery and development in oncology and immunology therapeutic areas, has raised nearly $150 million through a Series D funding round. The investment in the clinical stage company was led by Loyal Valley Capital (LVC) and Sino Biopharmaceutical. The co-investors in the Series D round are healthcare […]

Galecto Biotech secures €79m in Series C funding to advance idiopathic pulmonary fibrosis treatment

Galecto Biotech secures €79m in Series C funding to advance idiopathic pulmonary fibrosis treatment

Galecto Biotech, a Denmark-based pharmaceutical company specializing in galectin modulators for severe diseases like idiopathic pulmonary fibrosis (IPF) and cancer, has successfully raised €79 million through a Series C financing round. This funding was co-led by Ysios Capital and OrbiMed. New and Existing Investors Support Galecto Biotech’s Growth The Series C round saw participation from […]